Non-coding RNAS and uses thereof
Provided herein are compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, provided herein are non-coding RNAs as diagnostic markers and clinical targets for cancer.
1. A method of detecting a non-coding RNA in a subject, comprising
(a) contacting a biological sample comprising a prostate cancer cell or tissue from a subject with a gene expression detection assay, wherein said gene expression detection assay comprises a gene expression informative reagent for identification of the level of expression of SEQ ID NOs: 1710, 1277, and 614; and
(b) detecting the level of expression of said non-coding in said sample using an in vitro assay.
2. The method of claim 1 , wherein the sample is selected from the group consisting of tissue, blood, plasma, and serum.
3. The method of claim 1 , wherein detection is carried out utilizing a method selected from the group consisting of a sequencing technique, a nucleic acid hybridization technique, and a nucleic acid amplification technique.
4. The method of claim 3 , wherein the nucleic acid amplification technique is selected from the group consisting of polymerase chain reaction, reverse transcription polymerase chain reaction, transcription-mediated amplification, ligase chain reaction, strand displacement amplification, and nucleic acid sequence based amplification.
5. The method of claim 1 , wherein said reagent is selected from the group consisting of a pair of amplification oligonucleotides, a sequencing primer, and an oligonucleotide probe.
6. The method of claim 5 , wherein said reagent comprises one or more labels.
7. The method of claim 1 , further comprising detecting two or more additional non-coding RNAs.
8. The method of claim 1 , further comprising detecting ten or more additional non-coding RNAs.
9. The method of claim 1 , further comprising detecting one hundred or more additional non-coding RNAs.
10. The method of claim 1 , wherein said non-coding RNAs are converted to cDNA prior to or during detection.
11. The method of claim 1 , wherein said method further comprises detecting SEQ ID NO: 347.
12. The method of claim 1 , wherein said method further comprises the step administering a treatment for a prostate cancer to said subject based on said detecting the level of expression, wherein said treatment is an siRNA or an antisense oligonucleotide that blocks the expression or function of said non-coding RNA when expression of said non-coding RNA is present in said sample.